• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4614794)   Today's Articles (5891)   Subscriber (49390)
For: Fagin JA, Tuttle RM, Pfister DG. Harvesting the low-hanging fruit: kinase inhibitors for therapy of advanced medullary and nonmedullary thyroid cancer. J Clin Endocrinol Metab 2010;95:2621-4. [PMID: 20525911 PMCID: PMC2902070 DOI: 10.1210/jc.2010-0800] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]
Number Cited by Other Article(s)
1
Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR. Eur J Cancer 2021;157:153-164. [PMID: 34509954 DOI: 10.1016/j.ejca.2021.07.029] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2021] [Revised: 07/02/2021] [Accepted: 07/18/2021] [Indexed: 11/23/2022]
2
Cabanillas ME, Busaidy NL, Khan SA, Gunn GB, Dadu R, Rao SN, Waguespack SG. Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. INTERNATIONAL JOURNAL OF ENDOCRINE ONCOLOGY 2016. [DOI: 10.2217/ije-2016-0007] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022]  Open
3
Weitzman SP, Cabanillas ME. The treatment landscape in thyroid cancer: a focus on cabozantinib. Cancer Manag Res 2015;7:265-78. [PMID: 26316818 PMCID: PMC4547654 DOI: 10.2147/cmar.s68373] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]  Open
4
Wells SA, Santoro M. Update: the status of clinical trials with kinase inhibitors in thyroid cancer. J Clin Endocrinol Metab 2014;99:1543-55. [PMID: 24423326 PMCID: PMC5393476 DOI: 10.1210/jc.2013-2622] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
5
Oncogenic events and therapeutic targets in thyroid cancer. Mol Oncol 2013. [DOI: 10.1017/cbo9781139046947.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]  Open
6
Yuan MH, Zhou RS, She B, Xu HF, Wang JY, Wei LX. Expression and clinical significance of STIP1 in papillary thyroid carcinoma. Tumour Biol 2013;35:2391-5. [DOI: 10.1007/s13277-013-1316-8] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2013] [Accepted: 10/14/2013] [Indexed: 12/21/2022]  Open
7
Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases. Clin Cancer Res 2012;18:3532-40. [DOI: 10.1158/1078-0432.ccr-11-2700] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
8
Nowicki TS, Moscatello AL, Shin E, Schantz S, Tiwari RK, Geliebter J. The urokinase plasminogen activator system in metastatic papillary thyroid carcinoma: a potential therapeutic target. J Clin Endocrinol Metab 2011;96:3062-4. [PMID: 21832115 PMCID: PMC3417282 DOI: 10.1210/jc.2011-1123] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
9
Bales SR, Chopra IJ. Targeted treatment of differentiated and medullary thyroid cancer. J Thyroid Res 2011;2011:102636. [PMID: 21826256 PMCID: PMC3150151 DOI: 10.4061/2011/102636] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2011] [Accepted: 06/14/2011] [Indexed: 12/18/2022]  Open
10
Targeted therapies and thyroid cancer. Anticancer Drugs 2011;22:688-99. [DOI: 10.1097/cad.0b013e32834319c7] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
11
Rondeau G, Tuttle RM. Similarities and Differences in Follicular Cell-Derived Thyroid Cancer Management Guidelines Used in Europe and the United States. Semin Nucl Med 2011;41:89-95. [DOI: 10.1053/j.semnuclmed.2010.10.001] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
12
Nowicki TS, Zhao H, Darzynkiewicz Z, Moscatello A, Shin E, Schantz S, Tiwari RK, Geliebter J. Downregulation of uPAR inhibits migration, invasion, proliferation, FAK/PI3K/Akt signaling and induces senescence in papillary thyroid carcinoma cells. Cell Cycle 2011;10:100-7. [PMID: 21191179 DOI: 10.4161/cc.10.1.14362] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]  Open
13
Duntas LH, Bernardini R. Sorafenib: rays of hope in thyroid cancer. Thyroid 2010;20:1351-8. [PMID: 20954817 DOI: 10.1089/thy.2010.0056] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA